Wilex enters into manufacturing and distribution agreement with IBA Molecular
Wilex AG signed a contract with IBA Molecular N.A., Sterling, Virginia, USA. IBA delivers radiopharmaceuticals and isotopes for radiotherapy and radiodiagnosis. IBA will label the Wilex antibody WX-G250 with 124Iodine and will deliver it to the study centres participating in the pivotal trial for approval of the Wilex imaging diagnostic CA9-SCAN.
It is planned to enrol patients suspected of having kidney cancer in approximately 10 study centres in the USA and image them with CA9-SCAN prior to surgery. CA9-SCAN is a radioactively labelled form of the antibody WX-G250. The labelled antibody WX-G250 targets clear cell renal cell carcinoma and will accumulate in the tumour tissue. This accumulation can be visualised by means of Positron Emission Tomography (PET). An earlier feasibility study found that a positive result with CA9-SCAN could be confirmed as clear cell renal cell carcinoma in 100 % of the cases (positive predictive value). CA9-SCAN could determine whether the patient had clear cell renal cell carcinoma before the surgery and subsequent pathology. Therefore, CA9-SCAN should significantly improve and simplify treatment planning for patients suspected of having kidney cancer.
Other news from the department business & finance
